肠道菌群与非小细胞肺癌免疫治疗

聪 刘(内蒙古医科大学研究生院，中国)
丽 东(内蒙古自治区人民医院肿瘤内科，中国)
根 澈(内蒙古自治区人民医院肿瘤内科，中国)
畅 李(内蒙古自治区人民医院肿瘤内科，中国)
恬恬 朱(内蒙古自治区人民医院肿瘤内科，中国)

摘要

大多数非小细胞肺癌在诊断时转移出肺，不能通过手术切除。免疫治疗也成为非小细胞肺癌的重要治疗手段，特别是对于没有基因突变的非小细胞肺癌患者。尽管免疫治疗提高了非小细胞肺癌患者的总生存期及肿瘤无进展生存期，但其总体的5年生存率仅为9%~13%。因此，晚期非小细胞肺癌的治疗仍然是一个重要的医疗需要。而最新的研究表明，肠—肺轴微生态与肺部恶性肿瘤之间密切相关，肠道菌群可能通过“肠—肺轴微生态调控”发挥抑制肿瘤生长的作用。本综述将分析肠道菌群在非小细胞肺癌免疫治疗中的作用机制，为肺癌的治疗提供新的思路。

关键词

肠道菌群；免疫治疗；非小细胞肺癌

参考

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.

Chen DS, Mellman I. Oncology meets immunology: the cancerimmunity

cycle[J].Immunity,2013,39(1):1-10.

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy[J].Clin Oncol,2015,33(17):1974-1982.

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J].Nat Rev Cancer,2019,19(3):133-150.

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy[J].Cancer Discov,2018,8(9):1069-1086.

Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, effificacy, and limitations[J].Front Oncol,2018(8):86.

Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune -checkpoint inhibitors[J].Nat Rev Clin Oncol,2021,18(6):345-362.

Ribas A, Wolchok J D. Cancer immunotherapy using checkpoint blockade[J].Science,2018(359):1350-1355.

Zhao B, Zhao H Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials[J].Ther. Adv. Med. Oncol,2020(12):175-176.

Yusuke Tomita, Tokunori Ikeda.Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer[J].Cancer immunology research,2020,8(10):1236-1242.

.Li C, Lei S, Ding L, et al. Global burden and trends of lung cancer incidence and mortality[J].Chin Med J (Engl),2023(3):28.

Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer[J].N Engl J Med,2017,377(9):849-861.

Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer[J].Clin Oncol,2021(39):723-733.

Herbst RS, Garon EB, Kim DW, et al. 5-Year survival update from KEYNOTE-010: Pembrolizumab versus docetaxel for previously treated, programmed death ligand 1-positive advanced non-small-cell lung cancer[J].Thorac Oncol,2021(16):1718-1732.

Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: Final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials[J].Thorac Oncol,2021(16):140-150.

Peters S, Reck M, Smit EF, et al. How to make the best use of

immunotherapy as fifirst-line treatment of advanced/metastatic non-small-cell lung cancer[J].Ann Oncol,2019(30):884-8969.

Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J].Cell,2017(168):707-723.

Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J].Nat Med,2018(24):541-550.

Devaud C, John LB, Westwood JA, et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy[

J].Oncoimmunology,2013(2):25961.

Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies[J].Science,2018(359):1366-1370.

S R Gill M. Pop R. T. Deboy, et al. “Metagenomic analysis of the human distal gut microbiome”[J].Science, 2006(312):1355-1359.

R Bingula, M Filaire, N Radosevic-Robin, et al. “Desired turbulence?

Gut-lung axis, immunity, and lung cancer”[J].Journal of Oncology,2017(4):15.

Nešić D, Hsu Y, Stebbins CE. Assembly and function of a bacterial genotoxin[J].Nature,2018(7):29-31.

deMartel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis[J].Lancet Oncol,2012,13(6):607-615.

Fessler JL, Gajewski TF. The microbiota: a new variable impacting Cancer treatment outcomes[J].Clin Cancer Res,2017,23(13):3229-3231.

Meyer MS, Joshipura K, Giovannucci E, Michaud DS. A review of the relationship between tooth loss, periodontal disease, and cancer[J].Cancer Causes Control,2008,19(9):895-907.

Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis[J].PLoS One,2011,6(3):17479.

Clavel T, Gomes-Neto JC, Lagkouvardos I, et al. Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes[J].Immunol Rev,2017,279(1):8-22.

Marsland BJ, Yadava K, Nicod LP. The airway microbiome and disease[J].Chest,2013,144(2):632-637.

Chakradhar S. A curious connection: testing apart the link between gut microbes and lung dieseas[J].Nat Med,2017,23(4):402-404.

Sonnenburg ED, Smits SA, Tikhonov M, et al. Diet-induced extinctions in the gut microbiota compound overgenerations[J].Nature,2016,529(7585):212-315.

Caroline H Johnson M E. Spilker, LG, et al. Metabolite and microbiome

interplay in cancer immunotherapy[J].Cancer Res,2016,76(21):

-6152.

Chrystal M, Paulos CW, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling[J].Clin Invest,2007(117):2197-2204.

Baruch E N, et al. Fecal microbiota transplant promotes response

in immunotherapy refractory melanoma patients[J].Science,

(371):602-609.

Davar D, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J].Science,2021(371):595-602.

A Sivan, L Corrales, N Hubert, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[

J].Science, 2015(350):1084-1089.

Minlin Jiang, Peixin Chen, Lei Wang, et al. cGAS-STING, an important

pathway in cancer immunotherapy[J].Journal of hematology

& oncology,2020,13(1):81.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i3.16248